Inventor · disambiguated record
Susanne Kammler
Also filed as: KAMMLER SUSANNE
9 granted patents·11 pending applications·26 citations·filing 2012–2025
84Inventor score
Files withHOFFMANN LA ROCHE14ROCHE INNOVATION CT COPENHAGEN AS4SANTARIS PHARMA AS1UNIV DANMARKS TEKNISKE1
Top patents by PatentIndex Score
20 records- 0191US10953034B2Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infectionHOFFMANN LA ROCHE·Filed 2018·Granted Mar 23, 2021·5 cites·24 claims
- 0290US12303525B2Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infectionHOFFMANN LA ROCHE·Filed 2022·Granted May 20, 2025·1 cites·41 claims
- 0388US11484546B2Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infectionHOFFMANN LA ROCHE·Filed 2019·Granted Nov 1, 2022·3 cites·36 claims
- 0487US10077443B2Oligonucleotide conjugatesROCHE INNOVATION CT COPENHAGEN AS·Filed 2013·Granted Sep 18, 2018·10 cites·22 claims
- 0585US10358643B2Poly oligomer compound with biocleavable conjugatesHOFFMANN LA ROCHE·Filed 2015·Granted Jul 23, 2019·7 cites·18 claims
- 0675US2025319114A1NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTIONHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 0770US2024182898A1ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTELl EXPRESSIONHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 0868US11898145B2Enhanced oligonucleotides for inhibiting RTEL1 expressionHOFFMANN LA ROCHE·Filed 2022·Granted Feb 13, 2024·0 cites·17 claims
- 0968US2021238601A1Oligonucleotide ConjugatesROCHE INNOVATION CT COPENHAGEN AS·Filed 2021·Application pending·0 cites
- 1066US11155816B2Oligonucleotide conjugatesROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Granted Oct 26, 2021·0 cites·24 claims
- 1163US2020157546A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 1262US2022042022A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1358US12497621B2Oligonucleotides for modulating RTEL1 expressionHOFFMANN LA ROCHE·Filed 2021·Granted Dec 16, 2025·0 cites·8 claims
- 1456US2020399641A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 1556US2023263864A1Therapeutic microbesUNIV DANMARKS TEKNISKE·Filed 2021·Application pending·0 cites
- 1650US2016289677A1APOB Antisense Conjugate CompoundsROCHE INNOVATION CT COPENHAGEN AS·Filed 2014·Application pending·0 cites
- 1748US2019055564A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 1847US10519450B2Antisense oligonucleotides for modulating HTRA1 expressionHOFFMANN LA ROCHE·Filed 2017·Granted Dec 31, 2019·0 cites·42 claims
- 1943US2014343127A1Compounds for the modulation of smn2 splicingSANTARIS PHARMA AS·Filed 2012·Application pending·0 cites
- 2042US2015368642A1Lna oligonucleotide carbohydrate conjugatesHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Susanne Kammler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →